1303527-39-0Relevant articles and documents
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate
Ratcliffe, Paul,Adam, Julia M.,Baker, James,Bursi, Roberta,Campbell, Robert,Clark, John K.,Cottney, Jean E.,Deehan, Maureen,Easson, Anna-Marie,Ecker, Daniel,Edwards, Darren,Epemolu, Ola,Evans, Louise,Fields, Ruth,Francis, Stuart,Harradine, Paul,Jeremiah, Fiona,Kiyoi, Takao,McArthur, Duncan,Morrison, Angus,Passier, Paul,Pick, Jack,Schnabel, Peter G.,Schulz, Jurgen,Steinbrede, Heinz,Walker, Glenn,Westwood, Paul,Wishart, Grant,Haes, Joanna Udo De
, p. 2541 - 2546 (2011/06/17)
We report an expansion of the structure-activity relationship (SAR) of a novel series of indole-3-heterocyclic CB1 receptor agonists. Starting from the potent but poorly soluble lead, 1, a rational approach was taken in order to balance solubility, hERG a
